A 25-year-female with Diffuse Intrinsic Pontine Glioma Surviving for More than Nine Years Following Treatment with Antineoplastons

Rationale: Diffuse intrinsic pontine glioma (DIPG) is a lethal brain tumor and leading cause of tumor–related death in children. Over the past few decades, clinical trials have shown no improvement outcome. Most DIPGs occur pediatric population. Adult brainstem gliomas are rare, constitute less than 2% adult gliomas, show slight male predominance. The case this 25-year-old female presented to detail discuss use Antineoplastons A10 (Atengenal) AS2-1 (Astugenal) treatment DIPG that persisted despite radiation therapy (RT) temozolomide. Objectives: patient described was treated at Burzynski Clinic (BC), as special exception, according phase II protocol, BT-09, which utilized (ANP therapy) tumors. delivery ANP via subclavian catheter infusion pump. Tumor response measured by sequential magnetic resonance imaging (MRI) brain. Overall Survival (OS) Adverse Events (AES) were also documented. Findings: At her presentation BC, complained diplopia, left-sided weakness, difficulty walking. On physical exam, she alert orientated. Her cranial nerves intact. There weakness extremities. Deep tendon reflexes equal bilaterally with down-going toes bilaterally. Reports original MRIs Argentina suggested extension medulla cerebellum. In addition, biopsy confirmed grade 3 astrocytoma. Following temozolomide Argentina, BC for persistent disease therapy. Sequential MRI residual tumor, non-enhancing, showed change size during However, did achieve resolution neurologic signs symptoms has survived more nine years since first being seen BC. Correspondence on September 9, 2021 indicated feeling fine, had healthy child, enjoying life. Conclusions: We here an who after For patients (or other high-grade astrocytoma), do not qualify for/refuse RT or progressive following and/or chemotherapy, effective therapeutic option. collaboration FDA confirmatory Phase III studies been developed.